Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhC1INH for Acute HAE Attacks
NCT00262301Phase 3Completed
- Sponsor
- Pharming Group
- Start
- Jun 2004
- Primary completion
- Jul 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of c1-esterase inhibitor in hereditary angioedema (HAE) (2 arms), sponsored by Pharming Group. Primary endpoint: Time to Beginning of Relief of Symptoms up to 48 hours. Started Jun 2004; status: completed.
02
Drugs
c1-esterase inhibitor
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT00262301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00262301.